8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

[1]  E. Van Cutsem,et al.  Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Zoetmulder,et al.  Learning curve of combined modality treatment in peritoneal surface disease , 2007, The British journal of surgery.

[3]  L. Oñate-Ocaña,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. , 2007, Annals of surgical oncology.

[4]  C. Köhne,et al.  Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. , 2007, Cancer treatment and research.

[5]  P. Kam,et al.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  L. Oñate-Ocaña,et al.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement , 2006, Annals of Surgical Oncology.

[7]  H. Boot,et al.  Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  P. Sugarbaker.  A curative approach to peritoneal carcinomatosis from colorectal cancer. , 2005, Seminars in oncology.

[9]  P. Sugarbaker.  Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy. J Surg Oncol 2004; 85:61–67 , 2004, Journal of surgical oncology.

[10]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[12]  H. van Tinteren,et al.  Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy , 2004, The British journal of surgery.

[13]  A. Witkamp,et al.  Peritoneal carcinomatosis from colorectal or appendiceal origin: Correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement , 2004, Journal of surgical oncology.

[14]  H. Tinteren,et al.  Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy , 2004, Journal of surgical oncology.

[15]  A. Witkamp,et al.  Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin , 2004, Annals of Surgical Oncology.

[16]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Gilly,et al.  Natural history of peritoneal carcinomatosis from nongynecologic malignancies. , 2003, Surgical oncology clinics of North America.

[18]  P. Sugarbaker.  Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[19]  R. Goldberg,et al.  Review article: colorectal cancer chemotherapy. , 2003, Alimentary pharmacology & therapeutics.

[20]  D. Jayne,et al.  Peritoneal carcinomatosis from colorectal cancer , 2002, The British journal of surgery.

[21]  A. Witkamp,et al.  Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. , 2001, Cancer treatment reviews.

[22]  V. Eder,et al.  The value of immunoscintigraphy in the detection of recurrent colorectal cancer , 2001, Nuclear medicine communications.

[23]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Faure,et al.  Peritoneal carcinomatosis from non‐gynecologic malignancies , 2000, Cancer.

[25]  P. Sugarbaker.  Management of peritoneal-surface malignancy: the surgeon’s role , 1999, Langenbeck's Archives of Surgery.

[26]  S. Devesa,et al.  Incidence of colorectal carcinoma in the U.S. , 1999, Cancer.

[27]  P. Sugarbaker.  Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis , 1994, Diseases of the colon and rectum.

[28]  J. Spratt,et al.  Hyperthermic peritoneal perfusion system in canines. , 1980, Cancer research.